Oppenheimer reiterates an Outperform rating on Ideaya Biosciences (IDYA) with a $40 price target after the company announced that it met with ...

Oppenheimer analyst Matthew Biegler says Olema Oncology (OLMA) published a revised corporate deck today which included an update from the palazestrant plus ribociclib combination trial.

Oppenheimer slashed its price target on the ... sliding to $8.122, following the trial results. Q32 said a phase 2a trial for Bempikibart in treating alopecia areata (AA) showed “encouraging ...

Investment bank Oppenheimer cut its target price on Walmart to $95 per share, the lowest target tracked by Visible Alpha. The retailer could attract more shoppers stocking up on products ahead of ...